Liquid Biopsy Holds Its Own in Tumor Profiling.
Results from the largest liquid biopsy study to date indicate that the genetic changes detected by analyzing circulating tumor DNA in blood samples largely recapitulate those identified through conventional tissue biopsy. Sequencing circulating tumor DNA in plasma could be a useful option for monitoring the development of resistance to targeted therapy.